HAIRY CELL LEUKEMIA
Clinical trials for HAIRY CELL LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new HAIRY CELL LEUKEMIA trials appear
Sign up with your email to follow new studies for HAIRY CELL LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise for Hard-to-Treat blood cancers
Disease control CompletedThis study tested a combination of two drugs, acalabrutinib and pembrolizumab, in 161 people with various blood cancers such as lymphoma, leukemia, and multiple myeloma. The main goal was to check safety and side effects, while also seeing if the tumors shrank. The approach aims …
Matched conditions: HAIRY CELL LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Experimental drug combo targets tough blood cancers
Disease control CompletedThis early-stage trial tested a new drug called INCB040093, alone or combined with itacitinib, in 121 adults with B-cell cancers that had come back or stopped responding to treatment. The main goal was to find safe doses and check for side effects. Researchers also looked for sig…
Matched conditions: HAIRY CELL LEUKEMIA
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New combo aims to tame hairy cell leukemia with fewer side effects
Disease control CompletedThis study tested a combination of two drugs—vemurafenib (taken by mouth) and rituximab (given by IV)—in 15 people with hairy cell leukemia, a rare blood cancer. The goal was to see if this treatment works as well as or better than standard chemotherapy, but with fewer side effec…
Matched conditions: HAIRY CELL LEUKEMIA
Phase: PHASE2 • Sponsor: Scripps Health • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Targeted drug shows promise against rare leukemia
Disease control CompletedThis study tested a drug called vemurafenib (Zelboraf) in 36 people with hairy cell leukemia that had returned or not responded to standard therapy. The goal was to see how well the drug could clear leukemia from the blood and what side effects it caused. Vemurafenib works by blo…
Matched conditions: HAIRY CELL LEUKEMIA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC